PT  - JOURNAL ARTICLE
AU  - Kanjilal, Sanjat
AU  - Chalise, Sujata
AU  - Shah, Adnan Shami
AU  - Cheng, Chi-An
AU  - Senussi, Yasmeen
AU  - Uddin, Rockib
AU  - Thiriveedhi, Vamsi
AU  - Cho, Ha Eun
AU  - Carroll, Seamus
AU  - Lemieux, Jacob
AU  - Turbett, Sarah
AU  - Walt, David R
TI  - Performance of three rapid antigen tests against the SARS-CoV-2 Omicron variant
AID  - 10.1101/2022.02.17.22271142
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.17.22271142
4099  - http://medrxiv.org/content/early/2022/02/19/2022.02.17.22271142.short
4100  - http://medrxiv.org/content/early/2022/02/19/2022.02.17.22271142.full
AB  - Rapid antigen detection tests (RADTs) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now in widespread use in the United States. RADTs play an important role in maintaining an open society but require periodic reassessment to ensure test performance remains intact as the virus evolves. The nucleocapsid (N) protein is the target for the majority of RADTs and the SARS-CoV-2 Omicron variant has several N protein mutations that are previously uncharacterized. We sought to assess the impact of these mutations by testing 30 Omicron variant samples across a wide range of viral loads on three widely used RADTs: the iHealth COVID-19 Antigen Rapid Test, the ACON Laboratories FlowFlex COVID-19 Antigen Home Test, and the Abbott BinaxNOW COVID-19 Antigen Card, using 30 Delta variant samples as a comparator. We found no change in the analytic sensitivity of all three RADTs for detection of Omicron versus Delta, but noted differences in performance between assays. No RADT was able to detect samples with a cycle threshold (Ct) value of ≥27.5 for the envelope gene target on the Roche cobas RT-PCR assay. Epidemiologic studies are necessary to correlate these findings with their real-world performance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a grant from the Massachusetts Consortium for Pathogen Readiness.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was deemed non-human subjects research and approved by the Mass General Brigham Institutional Review Board (protocol 2021P003604).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors